Systemic mastocytosis

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Mast cells are ubiquitous, but are most numerous at anatomic sites that are in contact with the environment, such as in the mucosa of airways and gut, as well as in the skin. Although mast cells have long been identified as key cellular mediators of the allergic inflammatory response, 8-12 they have other physiological functions, including a role in innate immunity. 13-16 Mast cells mediate ‘early-phase’ (e.g. anaphylaxis, acute asthma) and ‘latephase ’ allergic responses, as well as non-type I hypersensi tivity reactions through release of mediators (vide infra). 17 Furthermore, mast cells mediate upregulation of Th2-responses and allergen-specific IgE biosynthesis, which contribute to host defenses against parasitic infections.18,19 Mast cells undergo activation, classically following cross-linking of Fc ε RI-bound IgE by multivalent allergen in sensitized individuals. Non-IgEtriggersformastcellmediator release include anaphylatoxins of the complement system (C3a and C5a), neuropeptides (e.g. vasoactive intestinal peptide, somatostatin, substance P), lipopolysaccharides (LPS), chemokines (e.g. CCL3/MIP1 α), and Tolllike receptors(TLR).13,14,16 Upon activation by either IgE-dependent or -independent mechanisms, the following mediators are released: (1) vasoactive amines, particularly histamine; (2) several distinct tryptases (α, β, and δ) that comprise the principal protein component of mast cells; (3) anionic proteoglycans (e.g. heparin, chondroitin sulphate) that confer metachromasia upon staining with toluidine blue; (4) various lipid mediators, these arachidonic acid-derived eicosanoids, which include leukotriene C4, leukotriene B4, and prostaglandin D2, mediate vasodilation, vasopermeability, smooth muscle constriction, mucus secretion, as well as other proinflammatory processes;(5)otherproteases (e.g. chymase, carboxypeptidaseA);and(6) specific cytokines.9,20-30 The latter recruit and activate specific cells, including basophils (IL-3), eosinophils (IL-5), neutrophils (tumor necrosis factor (TNF)- α /IL-8), and lymphocytes (IL-4/IL-13).

Original languageEnglish (US)
Title of host publicationChronic Myeloproliferative Disorders
PublisherCRC Press
Pages157-169
Number of pages13
ISBN (Electronic)9780203091616
ISBN (Print)9780415415989
StatePublished - Jan 1 2008

Fingerprint

Systemic Mastocytosis
Mast Cells
Immunoglobulin E
Allergens
Complement C3a
Complement C5a
Anaphylatoxins
Chymases
Chemokine CCL3
Prostaglandin D2
Tryptases
Leukotriene C4
Tolonium Chloride
Leukotriene B4
Interleukin-13
Basophils
Eicosanoids
Chondroitin Sulfates
Interleukin-3
Vasoactive Intestinal Peptide

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pardanani, A. D., & Tefferi, A. (2008). Systemic mastocytosis. In Chronic Myeloproliferative Disorders (pp. 157-169). CRC Press.

Systemic mastocytosis. / Pardanani, Animesh D; Tefferi, Ayalew.

Chronic Myeloproliferative Disorders. CRC Press, 2008. p. 157-169.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pardanani, AD & Tefferi, A 2008, Systemic mastocytosis. in Chronic Myeloproliferative Disorders. CRC Press, pp. 157-169.
Pardanani AD, Tefferi A. Systemic mastocytosis. In Chronic Myeloproliferative Disorders. CRC Press. 2008. p. 157-169
Pardanani, Animesh D ; Tefferi, Ayalew. / Systemic mastocytosis. Chronic Myeloproliferative Disorders. CRC Press, 2008. pp. 157-169
@inbook{f1daf3f2a10442d4bac34b036f793b95,
title = "Systemic mastocytosis",
abstract = "Mast cells are ubiquitous, but are most numerous at anatomic sites that are in contact with the environment, such as in the mucosa of airways and gut, as well as in the skin. Although mast cells have long been identified as key cellular mediators of the allergic inflammatory response, 8-12 they have other physiological functions, including a role in innate immunity. 13-16 Mast cells mediate ‘early-phase’ (e.g. anaphylaxis, acute asthma) and ‘latephase ’ allergic responses, as well as non-type I hypersensi tivity reactions through release of mediators (vide infra). 17 Furthermore, mast cells mediate upregulation of Th2-responses and allergen-specific IgE biosynthesis, which contribute to host defenses against parasitic infections.18,19 Mast cells undergo activation, classically following cross-linking of Fc ε RI-bound IgE by multivalent allergen in sensitized individuals. Non-IgEtriggersformastcellmediator release include anaphylatoxins of the complement system (C3a and C5a), neuropeptides (e.g. vasoactive intestinal peptide, somatostatin, substance P), lipopolysaccharides (LPS), chemokines (e.g. CCL3/MIP1 α), and Tolllike receptors(TLR).13,14,16 Upon activation by either IgE-dependent or -independent mechanisms, the following mediators are released: (1) vasoactive amines, particularly histamine; (2) several distinct tryptases (α, β, and δ) that comprise the principal protein component of mast cells; (3) anionic proteoglycans (e.g. heparin, chondroitin sulphate) that confer metachromasia upon staining with toluidine blue; (4) various lipid mediators, these arachidonic acid-derived eicosanoids, which include leukotriene C4, leukotriene B4, and prostaglandin D2, mediate vasodilation, vasopermeability, smooth muscle constriction, mucus secretion, as well as other proinflammatory processes;(5)otherproteases (e.g. chymase, carboxypeptidaseA);and(6) specific cytokines.9,20-30 The latter recruit and activate specific cells, including basophils (IL-3), eosinophils (IL-5), neutrophils (tumor necrosis factor (TNF)- α /IL-8), and lymphocytes (IL-4/IL-13).",
author = "Pardanani, {Animesh D} and Ayalew Tefferi",
year = "2008",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780415415989",
pages = "157--169",
booktitle = "Chronic Myeloproliferative Disorders",
publisher = "CRC Press",

}

TY - CHAP

T1 - Systemic mastocytosis

AU - Pardanani, Animesh D

AU - Tefferi, Ayalew

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Mast cells are ubiquitous, but are most numerous at anatomic sites that are in contact with the environment, such as in the mucosa of airways and gut, as well as in the skin. Although mast cells have long been identified as key cellular mediators of the allergic inflammatory response, 8-12 they have other physiological functions, including a role in innate immunity. 13-16 Mast cells mediate ‘early-phase’ (e.g. anaphylaxis, acute asthma) and ‘latephase ’ allergic responses, as well as non-type I hypersensi tivity reactions through release of mediators (vide infra). 17 Furthermore, mast cells mediate upregulation of Th2-responses and allergen-specific IgE biosynthesis, which contribute to host defenses against parasitic infections.18,19 Mast cells undergo activation, classically following cross-linking of Fc ε RI-bound IgE by multivalent allergen in sensitized individuals. Non-IgEtriggersformastcellmediator release include anaphylatoxins of the complement system (C3a and C5a), neuropeptides (e.g. vasoactive intestinal peptide, somatostatin, substance P), lipopolysaccharides (LPS), chemokines (e.g. CCL3/MIP1 α), and Tolllike receptors(TLR).13,14,16 Upon activation by either IgE-dependent or -independent mechanisms, the following mediators are released: (1) vasoactive amines, particularly histamine; (2) several distinct tryptases (α, β, and δ) that comprise the principal protein component of mast cells; (3) anionic proteoglycans (e.g. heparin, chondroitin sulphate) that confer metachromasia upon staining with toluidine blue; (4) various lipid mediators, these arachidonic acid-derived eicosanoids, which include leukotriene C4, leukotriene B4, and prostaglandin D2, mediate vasodilation, vasopermeability, smooth muscle constriction, mucus secretion, as well as other proinflammatory processes;(5)otherproteases (e.g. chymase, carboxypeptidaseA);and(6) specific cytokines.9,20-30 The latter recruit and activate specific cells, including basophils (IL-3), eosinophils (IL-5), neutrophils (tumor necrosis factor (TNF)- α /IL-8), and lymphocytes (IL-4/IL-13).

AB - Mast cells are ubiquitous, but are most numerous at anatomic sites that are in contact with the environment, such as in the mucosa of airways and gut, as well as in the skin. Although mast cells have long been identified as key cellular mediators of the allergic inflammatory response, 8-12 they have other physiological functions, including a role in innate immunity. 13-16 Mast cells mediate ‘early-phase’ (e.g. anaphylaxis, acute asthma) and ‘latephase ’ allergic responses, as well as non-type I hypersensi tivity reactions through release of mediators (vide infra). 17 Furthermore, mast cells mediate upregulation of Th2-responses and allergen-specific IgE biosynthesis, which contribute to host defenses against parasitic infections.18,19 Mast cells undergo activation, classically following cross-linking of Fc ε RI-bound IgE by multivalent allergen in sensitized individuals. Non-IgEtriggersformastcellmediator release include anaphylatoxins of the complement system (C3a and C5a), neuropeptides (e.g. vasoactive intestinal peptide, somatostatin, substance P), lipopolysaccharides (LPS), chemokines (e.g. CCL3/MIP1 α), and Tolllike receptors(TLR).13,14,16 Upon activation by either IgE-dependent or -independent mechanisms, the following mediators are released: (1) vasoactive amines, particularly histamine; (2) several distinct tryptases (α, β, and δ) that comprise the principal protein component of mast cells; (3) anionic proteoglycans (e.g. heparin, chondroitin sulphate) that confer metachromasia upon staining with toluidine blue; (4) various lipid mediators, these arachidonic acid-derived eicosanoids, which include leukotriene C4, leukotriene B4, and prostaglandin D2, mediate vasodilation, vasopermeability, smooth muscle constriction, mucus secretion, as well as other proinflammatory processes;(5)otherproteases (e.g. chymase, carboxypeptidaseA);and(6) specific cytokines.9,20-30 The latter recruit and activate specific cells, including basophils (IL-3), eosinophils (IL-5), neutrophils (tumor necrosis factor (TNF)- α /IL-8), and lymphocytes (IL-4/IL-13).

UR - http://www.scopus.com/inward/record.url?scp=85056529177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056529177&partnerID=8YFLogxK

M3 - Chapter

SN - 9780415415989

SP - 157

EP - 169

BT - Chronic Myeloproliferative Disorders

PB - CRC Press

ER -